Vildagliptin Attenuates Huntington's Disease through Activation of GLP-1 Receptor/PI3K/Akt/BDNF Pathway in 3-Nitropropionic Acid Rat Model.
Saved in:
| Title: | Vildagliptin Attenuates Huntington's Disease through Activation of GLP-1 Receptor/PI3K/Akt/BDNF Pathway in 3-Nitropropionic Acid Rat Model. |
|---|---|
| Authors: | Sayed NH; Department of Biochemistry, Faculty of Pharmacy, Cairo University, Governorate, Giza, Egypt., Fathy N; Department of Biochemistry, Faculty of Pharmacy, Cairo University, Governorate, Giza, Egypt. nevine.abdallah@pharma.cu.edu.eg., Kortam MA; Department of Biochemistry, Faculty of Pharmacy, Cairo University, Governorate, Giza, Egypt., Rabie MA; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Governorate, Giza, Egypt., Mohamed AF; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Governorate, Giza, Egypt., Kamel AS; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Governorate, Giza, Egypt. |
| Source: | Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics [Neurotherapeutics] 2020 Jan; Vol. 17 (1), pp. 252-268. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics Country of Publication: United States NLM ID: 101290381 Publication Model: Print Cited Medium: Internet ISSN: 1878-7479 (Electronic) Linking ISSN: 18787479 NLM ISO Abbreviation: Neurotherapeutics Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 31728850 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Vildagliptin Attenuates Huntington's Disease through Activation of GLP-1 Receptor/PI3K/Akt/BDNF Pathway in 3-Nitropropionic Acid Rat Model. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Sayed+NH%22">Sayed NH</searchLink>; Department of Biochemistry, Faculty of Pharmacy, Cairo University, Governorate, Giza, Egypt.<br /><searchLink fieldCode="AU" term="%22Fathy+N%22">Fathy N</searchLink>; Department of Biochemistry, Faculty of Pharmacy, Cairo University, Governorate, Giza, Egypt. nevine.abdallah@pharma.cu.edu.eg.<br /><searchLink fieldCode="AU" term="%22Kortam+MA%22">Kortam MA</searchLink>; Department of Biochemistry, Faculty of Pharmacy, Cairo University, Governorate, Giza, Egypt.<br /><searchLink fieldCode="AU" term="%22Rabie+MA%22">Rabie MA</searchLink>; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Governorate, Giza, Egypt.<br /><searchLink fieldCode="AU" term="%22Mohamed+AF%22">Mohamed AF</searchLink>; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Governorate, Giza, Egypt.<br /><searchLink fieldCode="AU" term="%22Kamel+AS%22">Kamel AS</searchLink>; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Governorate, Giza, Egypt. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101290381%22">Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics</searchLink> [Neurotherapeutics] 2020 Jan; Vol. 17 (1), pp. 252-268. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Inc%2E+on+behalf+of+American+Society+for+Experimental+NeuroTherapeutics%22">Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101290381 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1878-7479 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2218787479%22">18787479 </searchLink><i>NLM ISO Abbreviation: </i>Neurotherapeutics <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=31728850 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1007/s13311-019-00805-5 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 252 Titles: – TitleFull: Vildagliptin Attenuates Huntington's Disease through Activation of GLP-1 Receptor/PI3K/Akt/BDNF Pathway in 3-Nitropropionic Acid Rat Model. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Sayed NH – PersonEntity: Name: NameFull: Fathy N – PersonEntity: Name: NameFull: Kortam MA – PersonEntity: Name: NameFull: Rabie MA – PersonEntity: Name: NameFull: Mohamed AF – PersonEntity: Name: NameFull: Kamel AS IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 01 Text: 2020 Jan Type: published Y: 2020 Identifiers: – Type: issn-electronic Value: 1878-7479 Numbering: – Type: volume Value: 17 – Type: issue Value: 1 Titles: – TitleFull: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics Type: main |
| ResultId | 1 |